Pharmaceutical

Intellia’s gene editing therapy shows early potential in rare heart condition

Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in Chicago.

Nov 19, 2024 - 06:00
Intellia’s gene editing therapy shows early potential in rare heart condition
Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in Chicago.
Read the original article

Tags:

Previous Article

AstraZeneca picks first Treg cell therapy from Quell Therapeutics partnership

Next Article

Sandoz’s Afqlir gains EC marketing authorisation for retinal diseases

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: Eisai executive to retire; Express Scripts adds three Humira biosimilars to formulary

STAT+: Pharmalittle: Eisai executive to retire; Express...

Jul 12, 2023

STAT+: Biotech’s trade secrets face growing threat from foreign influences, science leaders warn

STAT+: Biotech’s trade secrets face growing threat from...

Jun 6, 2023

STAT+: Medicare’s new proposal to cover medical devices draws a mixed reaction

STAT+: Medicare’s new proposal to cover medical devices...

Jun 30, 2023